L-743,872
Pre-clinicalCompleted 0 watching 0 views this week๐ค Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Candidiasis, Esophageal
Conditions
Candidiasis, Esophageal, HIV Infections
Trial Timeline
โ โ โ
NCT ID
NCT00005921About L-743,872
L-743,872 is a pre-clinical stage product being developed by Merck for Candidiasis, Esophageal. The current trial status is completed. This product is registered under clinical trial identifier NCT00005921. Target conditions include Candidiasis, Esophageal, HIV Infections.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00005921 | Pre-clinical | Completed |
| NCT00005920 | Phase 2 | Terminated |
Competing Products
20 competing products in Candidiasis, Esophageal
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Micafungin | Astellas Pharma | Phase 1 | 33 |
| Isavuconazole + Caspofungin + Voriconazole | Astellas Pharma | Phase 3 | 77 |
| Micafungin + fluconazole | Astellas Pharma | Phase 3 | 77 |
| Micafungin (Mycamine) | Astellas Pharma | Phase 1 | 33 |
| Fluconazole + Micafungin | Astellas Pharma | Approved | 85 |
| Micafungin + Caspofungin | Astellas Pharma | Phase 3 | 77 |
| Micafungin + Fluconazole | Astellas Pharma | Phase 3 | 77 |
| Micafungin | Astellas Pharma | Phase 2 | 52 |
| micafungin + caspofungin | Astellas Pharma | Phase 3 | 77 |
| micafungin + amphotericin B deoxycholate | Astellas Pharma | Phase 3 | 77 |
| FK463 | Astellas Pharma | Phase 2 | 52 |
| Micafungin + Liposomal Amphotericin B | Astellas Pharma | Phase 3 | 77 |
| SHR8008 + Fluconazole | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| SHR8008 capsule + Fluconazole capsule | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| Caspofungin | Merck | Phase 2 | 52 |
| L-743,872 | Merck | Phase 2 | 52 |
| Caspofungin + Amphotericin B Deoxycholate | Merck | Phase 2 | 52 |
| Caspofungin acetate + Placebo | Merck | Phase 2 | 52 |
| Caspofungin + Normal Saline | Merck | Approved | 85 |
| caspofungin acetate | Merck | Phase 3 | 77 |